How are life-sciences companies valued?

By stage. Revenue-generating businesses are valued on margins, contracts and regulatory standing; development-stage companies on pipeline quality, IP strength and distance to value inflection points. Buyers review the evidence for each asset to assess its development stage, IP and regulatory position.

What does IP diligence involve?

Ownership chains verified back through founders, employees and research partners; patent coverage, life and geography; and freedom-to-operate analysis. IP assigned cleanly to the company, with documentation, is a precondition of value in this sector.

Who acquires or invests here?

International pharma and life-sciences strategics filling pipeline or capability gaps, and specialist investors. Processes are global by default, run in English against scientific, regulatory and IP diligence.

How does EU regulation enter the valuation?

Through the product pathway: authorisation status, manufacturing certifications and compliance history. Buyers use regulatory documentation, including correspondence, to assess the authorisation status and compliance history of marketed products and pipeline assets.

Does investment screening apply to our sector?

Health is among the critical sectors under the law of 14 July 2023, so control acquisitions by non-EU/EEA investors can require screening, judged by reference to the ultimate controlling investor. Where non-European capital is expected, counsel confirms scope before the process opens.

What local support exists for life-sciences companies?

Luxinnovation supports qualifying innovation projects, public research institutes provide collaboration capacity, and the SNCI offers medium and long-term financing for Luxembourg companies. Buyers review pipeline, IP and regulatory evidence alongside records of these operating-stage supports.

Healthcare

What Is a Pharma & Life Sciences Business Worth? – Luxembourg

A pharma & life sciences business typically sells for 9.1x to 16.4x EBITDA. Where yours lands depends on size, growth and owner dependence. Get your instant estimate in EUR below.

Pharma & Life Sciences Valuation Multiples

EBITDA Multiple12.74x typical

9.1x12.74x16.38x

Revenue Multiple4.55x typical

2.73x4.55x6.37x

Based on middle-market transaction data. Actual multiples vary based on company-specific factors.

Key Value Drivers for Pharma & Life Sciences

01Pipeline stage and probability of success
02Patent protection and exclusivity periods
03Commercial revenue and growth trajectory
04Partnership and licensing agreements
05Manufacturing capabilities and capacity

Calculate Your Pharma & Life Sciences Enterprise Value

Complete the form below to get your personalized enterprise value estimate in EUR

How to value a Pharma & Life Sciences business in Luxembourg

Pharma and life-sciences activity in Luxembourg is specialised rather than broad: development-stage companies, niche manufacturers, and services businesses around the industry, working within the EU regulatory framework and selling into European and global markets from the outset. Public research capacity, including the University of Luxembourg and national research institutes, forms part of the local science base.

Valuation logic splits by stage and model. Revenue-generating businesses (manufacturing, services, marketed products) are valued on margins, contract quality and regulatory standing. Development-stage companies are valued on pipeline: the clinical or technical stage of each asset, the strength of the underlying intellectual property, and the capital needed to reach value inflection points.

Intellectual property diligence covers ownership chains from founders and research partners, patent coverage and life, and freedom to operate. Regulatory diligence follows the product classification, from EU authorisation pathways to manufacturing certifications.

Buyers and investors are international: pharmaceutical and life-sciences strategics, and specialist investors. Health-related activities fall among the critical sectors in Luxembourg's 2023 investment screening law, relevant to non-EU/EEA acquisitions of control. Support through Luxinnovation and SNCI financing exists for qualifying companies at the operating stage.